Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin Academic Article uri icon

Overview

MeSH Major

  • Anemia
  • HIV Infections
  • Hepatitis C, Chronic
  • Intercellular Signaling Peptides and Proteins
  • Interferon-alpha
  • Polyethylene Glycols
  • Ribavirin

abstract

  • Growth factor supplementation and dose reduction do not seem to differ as management strategies for anemia and neutropenia in HIV/HCV-coinfected individuals treated with PEG-IFN/RBV.

publication date

  • November 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3386143

Digital Object Identifier (DOI)

  • 10.1097/QAI.0b013e3182324af9

PubMed ID

  • 21876446

Additional Document Info

start page

  • 261

end page

  • 8

volume

  • 58

number

  • 3